Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer.
J Immunother Cancer. 2021 Nov;9(11):e003237. doi: 10.1136/jitc-2021-003237.
J Immunother Cancer. 2021.
PMID: 34815355
Free PMC article.